Booster Therapeutics is a startup company developing drugs that degrade disease-causing proteins in cells, focusing initially on neurodegenerative diseases. Unlike current protein-degrading drugs, Booster’s approach targets the 20S proteasome, which can address multiple proteins without requiring a molecular tag. The company’s platform technology, DGRADX, uses computational techniques to understand the structure of the proteasome and automate screening for small molecule activators. Booster’s research has potential applications for diseases like Parkinson’s and Alzheimer’s. The company recently received $15 million in funding to advance its programs and continue pioneering the activation of the proteasome for therapeutic purposes.
Source link
Startup Booster Therapeutics Launches to Usher In Next Wave of Protein-Degrading Drugs
